Those two results answer different questions. One is a record of exposure at some point in your life, the other is a snapshot of whether viral genetic material is circulating in your blood right now. Read together, they tell a clinician whether anything needs to happen next.
A hepatitis C test looks for two separate things, almost always in sequence. The first is the hepatitis C antibody, a protein the immune system makes in response to the hepatitis C virus. The second, performed when the antibody screen is reactive, is viral RNA, the genetic material of the virus itself 1.
The distinction is the single most useful thing to understand about hepatitis C virus testing. An antibody is a memory. Once the immune system has produced antibodies against the virus, they generally remain detectable long after the infection itself has gone, so a reactive antibody result can reflect an infection that resolved years ago just as easily as one that is still present 1. Viral RNA is different. It is only there while the virus is replicating, so a nucleic acid test gives a direct read on current infection.
This is why the standard HCV test pathway is described as reflex testing. The laboratory runs the antibody immunoassay first because it is inexpensive and well suited to screening large numbers of people. If the result is reactive, the same blood sample, or a second sample, goes on for RNA testing rather than sending the person away with an ambiguous answer 1.
A third option, core antigen testing, detects a viral protein rather than viral genetic material and sits somewhere between the two in what it can tell you. It is covered further down this page.
The practical takeaway is that one result alone rarely finishes the story. If you have only had an antibody test, you know whether exposure happened. You do not yet know whether the virus is still there.
Hepatitis C often goes unnoticed because early and even long-standing infection frequently produces no symptoms that would send someone to a clinic. The virus can persist quietly in the liver while a person feels well, and liver injury accumulates slowly enough that it is not obvious from the outside.
That silence has two consequences. The first is that symptoms are a poor trigger for testing. By the time fatigue, abdominal discomfort or changes in skin and eye colour appear, liver scarring may already be established. The second is that people frequently have no memory of a specific exposure event. Transmission happens through blood-to-blood contact, and the circumstances in which that occurred can be decades in the past, minor at the time, or simply unknown.
Because of that, testing decisions cannot rest on how you feel. Research suggests that a strategy built only around recognised risk factors leaves a meaningful share of infections undetected, which is part of the reasoning behind broader adult testing 2. The counterpoint to the silence is that a single blood test resolves it, and that the testing pathway itself is short.
It is also worth separating two ideas that get blurred. Not every person exposed to the virus develops a long-term infection. A proportion clear the virus without any intervention, and in those people the antibody remains while the RNA does not 1. The only way to tell which group someone falls into is to test for RNA.
Most public health guidance has moved toward one-time testing for adults in general, rather than testing only people who report a recognised risk factor. Studies indicate that risk-based screening alone misses infections, because risk history is often unknown, unreported or simply forgotten 2.
One-time adult testing means exactly what it sounds like. A person who has never been tested has the test once, and if there is no ongoing exposure risk and the result is non-reactive, that question is usually settled. Repeat testing is the separate situation, and it applies to people with continuing exposure risk. How often that repeat testing should happen is a clinical judgement, not a fixed rule you can apply to yourself from a web page.
Situations that commonly prompt testing, or repeat testing, include the following.
Testing is also offered routinely in settings where the chance of finding undiagnosed infection is higher, and screening programmes have been described both inside and outside hospital settings 9.
If you are unsure whether any of this applies to you, that uncertainty is itself a reasonable reason to raise it with a clinician. The test is a standard blood test, and the question of who it applies to is answered far more easily by taking it than by reasoning through your own history.
The hepatitis C antibody test is an immunoassay that detects antibodies your immune system produced against viral proteins, and a reactive result means those antibodies were found. It does not mean the virus is currently in your blood 1.
Mechanically, the assay exposes your serum or plasma to fragments of hepatitis C virus protein fixed to a surface. If antibodies specific to those proteins are present, they bind, and the binding is turned into a measurable signal. Laboratories report the result as reactive or non-reactive, sometimes with a signal-to-cut-off value that indicates how strong the reaction was. A low signal just above the threshold is more likely to be a false reaction than a strongly positive one, which is one reason laboratories confirm rather than report in isolation 1.
The word reactive is deliberate. Laboratories use it in place of positive precisely because the result is a screening signal rather than a conclusion. A reactive antibody result tells you the immune system has encountered the virus. It does not distinguish between an infection that is active today, an infection that resolved on its own, or an infection that resolved after treatment.
This is also why antibody testing alone is not used to confirm anything. It is the entry point. The question it leaves open is answered by RNA.
An HCV RNA test detects the virus's genetic material directly, so it answers whether the infection is current. It is the confirmatory step after a reactive antibody screen 1.
Nucleic acid testing amplifies any viral genetic material present in the sample until it can be measured. Results come back as detected or not detected, and often with a viral load figure describing how much genetic material was found. For the purposes of confirming current infection, the detected or not detected part is what matters most. Viral load figures are used by clinicians for other purposes and are not something to interpret on your own.
RNA testing also becomes detectable earlier after exposure than antibody testing, because it does not wait for the immune system to mount a response 1. That makes it useful when exposure is recent and known.
There is a second role for RNA testing that comes later. Hepatitis C is curable with some medicines, and a clinician uses RNA testing after a course of treatment to check whether the virus remains detectable 3. Whether any treatment is appropriate, and what it would involve, is a decision that belongs to a licensed provider who has reviewed the full picture.
A cleared infection means antibodies are present but no viral genetic material is detectable, while a current infection means both are present. The combination of the two results is what separates them 1.
The table below shows how the common result combinations are usually read. These are general interpretations, and only a clinician who knows your history can apply them to you.
| Antibody result | RNA result | What it usually indicates |
|---|---|---|
| Non-reactive | Not usually performed | No antibodies found. Past or current infection is unlikely, although very recent exposure may not show yet |
| Reactive | Detected | Current infection, worth discussing with a clinician promptly |
| Reactive | Not detected | Past exposure with no detectable virus now, either cleared without intervention or after treatment |
| Non-reactive, with recent exposure or weakened immunity | May be ordered directly | The antibody result may be unreliable, so a clinician may move straight to RNA testing |
Two points often surprise people. The first is that clearing the virus does not clear the antibody. Someone who resolved an infection twenty years ago will usually still screen reactive, and that reactive result is not a sign that something is wrong. The second is that clearing the virus once does not make a person immune to it. Reinfection is possible if blood-to-blood exposure happens again, which is why people with ongoing exposure risk are offered repeat RNA testing rather than relying on a historical result.
Like any screening test, hepatitis C testing can produce false reactive and false non-reactive results, which is exactly why the pathway is built as two steps rather than one 1.
False reactive antibody results are more likely when testing is done across a population where infection is uncommon. The lower the true frequency of infection in the group being tested, the larger the proportion of reactive results that turn out not to reflect real exposure, and confirmatory RNA testing is what resolves this 1. A weak reactive signal on the assay is more likely to fall into this category than a strong one.
False non-reactive results have different causes. The most common is timing, where the sample was collected before antibodies had developed. The other is a blunted antibody response, which can occur in people with significantly weakened immune function and in people on long-term haemodialysis 1. In those situations a clinician may order RNA testing directly rather than relying on the antibody screen as a gatekeeper.
Sample handling and laboratory error are rarer explanations, but they exist, and they are one reason an unexpected result is often repeated on a fresh sample before anything else happens. None of this is a reason to dismiss a result. It is a reason to complete the pathway rather than stopping halfway through it.
There is a window period after exposure during which a hepatitis C test can be negative even though infection has occurred, and RNA becomes detectable earlier in that window than antibody does 1.
The reason is biological. Viral replication begins first, so genetic material appears in the blood before the immune system has had time to generate a detectable antibody response. Antibody production takes longer, and the exact interval varies between individuals.
For a known, recent, specific exposure, this matters a great deal, and a clinician will decide which test to use and when to repeat it. For the far more common situation, where someone is being tested because they have never been tested before and there is no recent exposure event, the window period is not a practical concern. Any exposure would be well outside it.
Where the window period causes real trouble is when a person tests early, receives a non-reactive result, and treats it as a permanent answer despite ongoing exposure risk. If exposure risk is current, the result describes the past, not the future, and the timing of repeat testing is a question for a clinician.
Most hepatitis C testing uses a standard venous blood draw, but fingerstick rapid tests, dried blood spot cards and point-of-care molecular platforms all exist and are used where a conventional laboratory draw is impractical 4.
| Test format | What it detects | Question it answers | Typical sample |
|---|---|---|---|
| Laboratory antibody immunoassay | Antibodies to the virus | Has exposure ever happened | Venous blood |
| Laboratory HCV RNA test | Viral genetic material | Is the infection current | Venous blood |
| HCV core antigen test | A viral protein present during active infection | Is the infection current | Venous blood |
| Rapid point-of-care antibody test | Antibodies, read within minutes | Has exposure ever happened | Fingerstick blood or oral fluid |
| Dried blood spot card | Antibody or viral genetic material, depending on the assay | Either, depending on what is requested | Fingerstick blood dried on a card |
Rapid tests exist because the conventional pathway loses people between steps. Research suggests that rapid and point-of-care screening tests for hepatitis C have high accuracy, with the strongest performance seen on blood samples rather than oral fluid 6. That makes them practical in settings where a person may not return for a second appointment.
Dried blood spot sampling solves a different problem, which is getting a usable sample from someone who cannot easily reach a phlebotomy service or whose veins are difficult to access. Studies suggest that dried blood spot samples can detect hepatitis C antibody and viral genetic material with accuracy close to standard venous samples 7.
The broader goal behind all of these formats is a single visit result, so that screening and confirmation happen before the person leaves 5. No fasting or special preparation is needed for hepatitis C testing itself, although other markers drawn at the same time may have their own requirements.
HCV core antigen testing detects a structural protein of the virus rather than its genetic material, and it is used as an alternative marker of current infection where RNA testing is not readily available 4.
The appeal is logistical. Core antigen assays can run on the same high-throughput immunoassay analysers that laboratories already use for antibody testing, which avoids the specialised equipment and handling that nucleic acid amplification requires. That shortens the path from reactive antibody to a confirmed answer in settings where sending a sample to a molecular laboratory introduces days or weeks of delay.
Research suggests that core antigen testing identifies current hepatitis C infection with high specificity, including among people living with hepatitis B 8. The trade-off is sensitivity at low viral levels, where genetic material may be detectable but the protein is not. For that reason core antigen is generally positioned as a practical confirmatory option rather than a universal replacement for RNA testing, and which assay is appropriate for a given person is a clinical decision.
ALT is a liver enzyme that reflects liver cell turnover, not the presence of a virus, so it can sit inside the standard range while an infection is active. Typical lab reference ranges for ALT run roughly 7 to 56 U/L in men and 7 to 33 U/L in women, while FitScript's optimal range is 10 to 25 U/L in men and 8 to 19 U/L in women, an optimization target rather than a diagnostic cut-off. Reference ranges vary by lab, age and sex.
A normal ALT neither rules hepatitis C in nor out, and an elevated ALT has many possible explanations unrelated to it. The dedicated ALT guide covers what the marker measures, how it is tested and how to read a result in context.
Hepatitis C testing is usually interpreted next to a broader liver and bloodborne infection picture, because the virus is only one of several things that can affect liver function and because co-infection changes how a clinician approaches the result.
A typical surrounding panel includes AST alongside ALT, alkaline phosphatase, total and direct bilirubin, albumin and total protein. Platelet count is informative too, since falling platelets can accompany advanced liver scarring. Prothrombin time or INR reflects the liver's synthetic capacity. Hepatitis B surface antigen testing is frequently ordered at the same time, because the routes of transmission overlap and because the presence of one bloodborne infection raises the value of checking for the others.
Beyond that, a clinician may assess the degree of liver fibrosis using non-invasive scoring based on routine blood values, imaging, or elastography. None of that is something to arrange or interpret independently, but it explains why a confirmed current infection usually leads to more testing rather than straight to a conclusion.
For context on how this sits inside a wider testing programme, FitScript tests 150+ biomarkers per year, Atlas, its AI health advisor, interprets the results, and a licensed provider decides on any treatment that follows.
Several things can shift a hepatitis C test result or complicate its interpretation, and most of them relate to timing, immune function and what else is going on in the liver.
Timing is the big one. A sample drawn inside the window period can be non-reactive despite infection, and that is a property of the biology rather than a fault in the test 1. Immune status is the second. A blunted antibody response in people with significantly weakened immunity or on long-term haemodialysis can produce a non-reactive antibody result where RNA testing would find the virus 1.
Other factors do not change the hepatitis C result itself but change how the surrounding liver markers read. Alcohol intake, substantial fat accumulation in the liver, recent intense exercise, other viral infections and some medicines can all move liver enzymes. If you take anything regularly, ask your prescriber whether it is relevant to your liver results rather than drawing conclusions from the numbers alone.
Finally, sample handling matters more for molecular testing than for antibody testing, because viral genetic material degrades if a sample is not processed appropriately. This is a laboratory-side issue, and it is one reason an unexpected not detected result in a person with a strongly reactive antibody may be repeated.
When RNA testing confirms a current infection, the next steps belong to a clinician, who will usually assess the state of the liver, check for co-infections and discuss options.
That assessment typically includes liver enzymes, synthetic function markers, platelet count, imaging in some cases, and an estimate of fibrosis. The purpose is to understand how much the liver has been affected, which informs both urgency and follow-up. Hepatitis C is curable with some medicines, and whether any of them are appropriate for a given person is something a licensed provider evaluates after reviewing the whole picture. Treatment decisions belong to a licensed provider.
After treatment, RNA testing is repeated to check whether the virus remains detectable 3. Follow-up does not necessarily stop there, because a liver that has already sustained scarring continues to need monitoring regardless of whether the virus is gone, and because reinfection remains possible where exposure risk continues.
There is also a practical dimension. Simplifying the pathway from screening to confirmation to care has been a stated aim in the field, precisely because people drop out between steps 4. If you have a reactive antibody result and no RNA result, completing that second step is the single most useful thing you can do.
It is worth speaking to a clinician if you have never been tested, if you have a reactive antibody result without a follow-up RNA result, or if you have ongoing exposure risk and your last test is not recent.
Some situations warrant a prompt conversation rather than a routine one. A confirmed detectable RNA result is worth discussing with a clinician promptly. So are liver markers well outside the standard range, yellowing of the skin or eyes, swelling of the abdomen or legs, dark urine, persistent confusion or unusual bruising and bleeding. Those features can reflect advanced liver disease and are not something to monitor at home.
Equally, a non-reactive result in someone with continuing exposure risk is a reason to agree a repeat testing schedule rather than to close the question. Screening programmes exist in both hospital and community settings, and access routes vary by health system 9.
This page is educational and is not medical advice. Discuss your results and any treatment with a clinician or licensed provider who can see your full history.
For related reading, the guide to cirrhosis symptoms covers the signs that can point toward advanced liver scarring and when they warrant attention.
The antibody test shows whether your immune system has ever responded to the hepatitis C virus. The RNA test looks for the virus's genetic material and shows whether an infection is present right now. The antibody test is the screening step and the RNA test is the confirming step.
Not on its own. A reactive result means antibodies were detected, and antibodies can remain in the blood long after an infection has resolved. An RNA test is needed to tell whether the virus is currently present, and a clinician interprets the two results together.
There is a window period during which a test can come back negative even though infection has occurred. The RNA test becomes detectable earlier than the antibody test, because it does not wait for an immune response to build. If you have had a specific recent exposure, a clinician will decide which test to use and when to repeat it.
No, hepatitis C antibody and RNA testing do not require fasting or any special preparation. Other markers drawn from the same sample, such as glucose or a lipid panel, may have their own requirements. Check with the lab or clinic when you book.
Yes, fingerstick rapid tests and dried blood spot cards are used in settings where a venous draw is impractical. A reactive result from any of these formats still needs a confirmatory step to establish whether the infection is current. Which format is used depends on the service and what the clinician is trying to answer.
Usually yes. Antibodies generally persist long after the virus has gone, so people who cleared an infection years ago often continue to screen reactive. That is why a reactive antibody result in someone with a known history is not itself a sign of current infection, and RNA testing settles the question.
Yes. Clearing the virus does not produce lasting immunity, so reinfection is possible if blood-to-blood exposure happens again. People with ongoing exposure risk are usually offered repeat RNA testing rather than relying on a past result, and a clinician decides how often that should happen.
Contact a clinician promptly so the result can be reviewed in context. They will usually assess the state of the liver, check for other bloodborne infections and discuss what happens next. Any decision about treatment belongs to a licensed provider who has reviewed your full history.